Payload Information
General Information of This Payload
| Payload ID | PAY0CBOGD |
|||||
|---|---|---|---|---|---|---|
| Name | Dolicatatin 5 |
|||||
| Synonyms |
Dolicatatin 5
Click to Show/Hide
|
|||||
| Target | Microtubule (MT) | |||||
| Structure |
|
|||||
| Formula | C40H69N9O6 |
|||||
| Isosmiles | CC([C@H](N(C)C)C(N[C@@H](C(C)C)C(N(C)C([C@H](OC)CC(N1CCC[C@H]1[C@H](OC)[C@H](C(N[C@H](CN=[N+]=[N-])CC2=CC=C(N)C=C2)=O)C)=O)[C@H](CC)C)=O)=O)C |
|||||
| InChI |
InChI=1S/C40H69N9O6/c1-13-26(6)36(48(10)40(53)34(24(2)3)45-39(52)35(25(4)5)47(8)9)32(54-11)22-33(50)49-20-14-15-31(49)37(55-12)27(7)38(51)44-30(23-43-46-42)21-28-16-18-29(41)19-17-28/h16-19,24-27,30-32,34-37H,13-15,20-23,41H2,1-12H3,(H,44,51)(H,45,52)/t26-,27+,30-,31-,32+,34-,35-,36?,37+/m0/s1
|
|||||
| InChIKey |
QIHHTRNUHMRKQK-QDYXTHCGSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
772.049 |
Polar area |
195.3 |
||
Complexity |
1365.212769 |
xlogp Value |
4.2537 |
|||
Heavy Count |
55 |
Rot Bonds |
22 |
|||
Hbond acc |
9 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
MORAb-003 ADC13 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | High FRA expression (FRA +++) | ||
| Method Description |
Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
|
||||
| In Vitro Model | Osteosarcoma | SJSA-1 cells | CVCL_1697 | ||
MORAb-003 ADC33 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | High FRA expression (FRA +++) | ||
| Method Description |
Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
|
||||
| In Vitro Model | Osteosarcoma | SJSA-1 cells | CVCL_1697 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
144 nM
|
High FRA expression (FRA +++) | ||
| Method Description |
Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
|
||||
| In Vitro Model | Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma | IGROV1 cells | CVCL_1304 | ||